Prelude Therapeutics (PRLD) Accumulated Expenses (2019 - 2026)

Prelude Therapeutics has disclosed Accumulated Expenses across 8 years of filings, most recently posting $2.5 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $2.5 million, down 77.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 million (down 77.58% YoY), and the FY2025 annual result was $12.5 million, down 17.59% from the prior year.
• Accumulated Expenses came in at $2.5 million for Q1 2026 at Prelude Therapeutics, down from $12.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $15.8 million in Q4 2023 to a low of $2.5 million in Q1 2026.
• The 5-year median for Accumulated Expenses is $10.1 million (2024), against an average of $9.3 million.
• Across the five-year window, Accumulated Expenses soared 231.16% in 2022 and sank 77.58% in 2026, its largest moves.
• Prelude Therapeutics' Accumulated Expenses stood at $13.1 million in 2022, then climbed by 20.43% to $15.8 million in 2023, then fell by 3.55% to $15.2 million in 2024, then retreated by 17.59% to $12.5 million in 2025, then slumped by 79.78% to $2.5 million in 2026.
• The last three Accumulated Expenses figures came in at $2.5 million (Q1 2026), $12.5 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.